All the top Biotech & Pharma news in one daily newsletter.

What to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear from you!📣

(You can also reach out to me on LinkedIn)

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

BONUS CONTENT
Autoimmune Cell Therapy

We’ve put together an overview and infographic on the autoimmune cell therapy space - you can check that out here.

THE GOOD
Approvals & Labels

Phathom Pharmaceuticals’ Voquezna (vonoprazan) lands FDA approval for non-erosive GERD
Small molecule, non-erosive gastroesophageal reflux disease - Read more

THE GOOD
Business Development

Exscientia buys back CDK7 drug from partner GT Apeiron for $20M
Small molecule, combo therapy, breast cancer - Read more

Inventiva issues €20.1M ($21.9M) worth of royalty certificates for their future NASH/MASH asset (currently in Ph3)
Small molecule, metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH) - Read more

OPKO Health, HealthCare Royalty enter into $250 Million note purchase agreement,
Protein, human growth hormone, pediatric growth hormone deficiency - Read more

THE GOOD
Clinical Trials

World first - autoimmune patients respond to allogeneic CAR-T treatment
Allogeneic CAR-T cell therapy, immune-mediated necrotizing myopathy (IMNM), diffuse cutaneous systemic sclerosis (dcSSc) - Read more 

Pfizer, Valenva tick off primary vaccinations of participants in their Ph3 Lyme disease vaccine trial
Vaccine, Lyme disease - Read more 

Roche touts Ph3 durability of Vabysmo in eye diseases and in recently relaunched eye implant Susvimo
Monoclonal antibody, diabetic retinopathy, diabetic macular edema - Read more

Teva Pharmaceuticals’ Ph3 success in paediatric migraine prevention
Monoclonal antibody, paediatric migraine prevention - Read more

THE GOOD
Earnings & Finances

Johnson & Johnson depression med near-blockbuster status bodes well for psychedelics
Small molecule, treatment-resistant depression, major depressive disorder - Read more

Novartis beats Q2 estimates thanks to blockbusters
Monoclonal antibody, small molecule, heart failure, arthritis - Read more

Abbott bumps up full-year forecast after low double-digit sales growth in Q2
Medical device - Read more

THE GOOD
Fundraises

TMRW Life Sciences $28M Series D
Fertility, egg freezing - Read more [Paywall]

Novocuff $26M Series A
Medical device, preterm birth, cervical shortening, premature rupture of membranes - Read more

THE GOOD
Investments

Parker Institute will invest $125M into bringing cell therapies closer to front-line use
Cell therapy - Read more

THE GOOD
Partnerships

GSK, Sanofi, Denali participate in Foundation for the National Institutes of Health Parkinson’s biomarker project
Parkinson’s disease, unique biomarker study - Read more

Good news as GoodRx and Boehringer Ingelheim strike partnership to make Humira biosimilar available at discounted price
Monoclonal antibody, autoimmune, anti-inflammatory, biosimilar - Read more

Takeda, nference partner on AI-powered IDB care
AI, personalized, inflammatory bowel disease - Read more

THE GOOD
Research

“The Next Berlin Patient” - 7th person ever seemingly cured of HIV infection
Human immunodeficiency virus, acquired immunodeficiency syndrome - Read more

KRAS cancer drug eases symptoms of ultra-rare blood vessel condition in two patients; study
Small molecule, severe arteriovenous malformations - Read more [Paywall]

THE GOOD
Strategic Plans

argenx showcases big 2030 plans at their R&D day
Antibody fragment, myasthenia gravis - Read more

Novartis isn’t planning on being a late entrant to the GLP-1 obesity game, but they still have a few potential aces in the works
GLP-1, obesity - Read more

ENJOYING THESE NEWSLETTERS?
Consider an optional paid subscription.

It’s a lot of work to put together a daily newsletter, and it’s currently just me writing these things (+ one part-time contractor - no fancy editing team!).

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.

THE BAD
Approvals & Labels

FDA “advises against” Agenus applying for accelerated approval for their colorectal cancer combo therapy
Monoclonal antibody, combo therapy, colorectal cancer - Read more

THE BAD
Clinical Trails

AVEO Oncology uh oh as kidney cancer combo flunks Ph3
Monoclonal antibody, small molecule, combo therapy, renal cell carcinoma - Read more

Novartis waits on more clinical data from €2.7B ($2.9B) MorphoSys acquired myelofibrosis asset before attempting filing
Small molecule, myelofibrosis - Read more

THE BAD
Earnings & Finance

Despite beatings Q2 earnings, Novartis stock takes hit after ditching KRAS-blocking cancer drug due to incumbent competitors Amgen, Bristol Myers Squibb
Small molecule, cancer - Read more 

THE BAD
Marketing

PhRMA isn’t beneath running attack ads, blaming PBMs for drug pricing
Drug pricing, lobby, pharmacy benefit manager - Read more

THE BAD
Partnerships

Insult to injury; Johnson & Johnson ditches Addex Therapeutics partnership after latter’s epilepsy treatment flunks in Ph2
Small molecule, epilepsy - Read more

THE BAD
Research

Despite FDA green light for non-animal models in R&D, regulatory concerns still persist (and hinder their adoption)
Non-animal models, drug development - Read more

THE UGLY
Lawsuits

Ardelyx sues Medicare/medicaid (CMS) over phosphate-lowering therapies coverage
US Department of Health & Human Services, Centers for Medicare and Medicaid Services, reimbursement, small molecule - Read more

THE UGLY
Marketing

AstraZeneca “skewered” by UK marketing watchdog
Drug marketing, Prescription Medicines Code Of Practice Authority - Read more

THE UGLY
Patient Access

Between the obesity/GLP-1 craze and Novo Nordisk discontinuing long-acting insulting Levemir, insulin users fear being left behind
Insulin, diabetes - Read more [Paywall]

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Want to sponsor this newsletter and reach an audience of 550+ biotech and pharma professionals? Reach us here. 👍

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here.